Natixis Asset Management Boosts Position in Alnylam Pharmaceuticals, Inc. (ALNY)
Natixis Asset Management increased its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 370.3% during the third quarter, Holdings Channel reports. The firm owned 12,689 shares of the biopharmaceutical company’s stock after buying an additional 9,991 shares during the period. Natixis Asset Management’s holdings in Alnylam Pharmaceuticals were worth $860,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in ALNY. Calvert Investment Management Inc. raised its stake in shares of Alnylam Pharmaceuticals by 0.8% in the second quarter. Calvert Investment Management Inc. now owns 4,313 shares of the biopharmaceutical company’s stock worth $239,000 after buying an additional 36 shares during the last quarter. IBM Retirement Fund raised its stake in shares of Alnylam Pharmaceuticals by 1.0% in the second quarter. IBM Retirement Fund now owns 7,559 shares of the biopharmaceutical company’s stock worth $419,000 after buying an additional 76 shares during the last quarter. Mn Services Vermogensbeheer B.V. raised its stake in shares of Alnylam Pharmaceuticals by 4.6% in the third quarter. Mn Services Vermogensbeheer B.V. now owns 1,974 shares of the biopharmaceutical company’s stock worth $134,000 after buying an additional 87 shares during the last quarter. Fayerweather Charles raised its stake in shares of Alnylam Pharmaceuticals by 3.5% in the second quarter. Fayerweather Charles now owns 4,165 shares of the biopharmaceutical company’s stock worth $231,000 after buying an additional 140 shares during the last quarter. Finally, Hsbc Holdings PLC raised its stake in shares of Alnylam Pharmaceuticals by 1.5% in the third quarter. Hsbc Holdings PLC now owns 10,047 shares of the biopharmaceutical company’s stock worth $681,000 after buying an additional 151 shares during the last quarter. 89.71% of the stock is currently owned by institutional investors.
Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) traded down 0.57% during midday trading on Friday, reaching $41.60. The company had a trading volume of 1,030,670 shares. The firm’s 50 day moving average price is $42.52 and its 200-day moving average price is $55.82. Alnylam Pharmaceuticals, Inc. has a 12 month low of $31.38 and a 12 month high of $83.42. The company’s market capitalization is $3.57 billion.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its earnings results on Wednesday, November 2nd. The biopharmaceutical company reported ($1.21) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.14) by $0.07. The company had revenue of $13.70 million for the quarter, compared to the consensus estimate of $9.14 million. Alnylam Pharmaceuticals had a negative return on equity of 33.97% and a negative net margin of 1,041.16%. The firm’s revenue was up 116.7% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.91) earnings per share. Analysts anticipate that Alnylam Pharmaceuticals, Inc. will post ($4.80) earnings per share for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: This news story was published by Watch List News and is the sole property of of Watch List News. If you are accessing this news story on another domain, it was illegally copied and reposted in violation of international copyright laws. The legal version of this news story can be read at http://www.watchlistnews.com/natixis-asset-management-boosts-position-in-alnylam-pharmaceuticals-inc-alny/1060783.html.
A number of analysts have recently issued reports on ALNY shares. Leerink Swann reaffirmed a “buy” rating on shares of Alnylam Pharmaceuticals in a research report on Monday, September 26th. FBR & Co reissued an “outperform” rating and issued a $180.00 price objective on shares of Alnylam Pharmaceuticals in a report on Tuesday, September 27th. Janney Montgomery Scott started coverage on Alnylam Pharmaceuticals in a report on Wednesday, September 28th. They issued a “neutral” rating and a $74.00 price objective for the company. Jefferies Group set a $86.00 price objective on Alnylam Pharmaceuticals and gave the company a “buy” rating in a report on Wednesday, September 28th. Finally, Credit Suisse Group set a $145.00 price objective on Alnylam Pharmaceuticals and gave the company a “buy” rating in a report on Friday, September 30th. Seven investment analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and an average price target of $67.64.
In related news, CMO Akshay Vaishnaw sold 29,165 shares of the stock in a transaction on Wednesday, November 30th. The shares were sold at an average price of $44.99, for a total transaction of $1,312,133.35. Following the transaction, the chief marketing officer now directly owns 34,915 shares of the company’s stock, valued at $1,570,825.85. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 4.00% of the company’s stock.
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in developing therapeutics based on ribonucleic acid (RNA) interference (RNAi). It is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate strategy for delivery of small interfering RNAs (siRNAs). Its pipeline of investigational RNAi therapeutics focuses in three Strategic Therapeutic Areas (STArs): Genetic Medicines; Cardio-Metabolic Disease, and Hepatic Infectious Disease.
Want to see what other hedge funds are holding ALNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY).
Receive News & Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.